You are here: Industry Insights > Merck

News List

Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action fiercepharma
August 06, 2018
Merck & Co. likely expected big numbers from Eisai’s Lenvima when it agreed in March to fork over $5.8 billion to share rights to the drug. And those numbers are rolling in.
Merck gets Chinese approval for Keytruda to treat skin cancer pharmaceutical-technology
July 31, 2018
Merck has secured approval from the China National Drug Administration (CNDA) for the use of its Keytruda medicine to treat adults suffering from unresectable or metastatic melanoma.
European backing for Merck's Keytruda rubs salt in Bristol-Myers' wounds biospectrumasia
July 31, 2018
Merck’s Keytruda is one step closer to extending its dominance in the all-important previously untreated lung cancer market.
Merck’s formulation steps further for approval in 21 EU countries biospectrumasia
July 30, 2018
BfArM is acting as a representative of all 21 EU countries involved in the EU worksharing procedure
Merck's Keytruda shores up head and neck case with first-line trial win biospectrumasia
July 26, 2018
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions.
10 years after a rejection, Merck returns to the FDA with a Gardasil 9 age expansion bid fiercevaccines
July 23, 2018
How long is a drugmaker willing to wait on an indication expansion plan? For Merck’s HPV vaccines, that's 10 years.
GlaxoSmithKline to pass $10B in 2024 vaccine sales, with Merck, Sanofi and Pfizer rounding out the top 4: report fiercevaccines
July 23, 2018
Shingrix may not make it on the top five best-selling vaccines list in 2024, but a diversified portfolio will still secure GlaxoSmithKline the lead position in the vaccine industry at that time, followed by Merck &Co., Sanofi, Pfizer and a dark horse biot
Merck’s price cuts are flashy, but no more benevolent than Pfizer’s freeze: analysts fiercepharma
July 23, 2018
Little more than a week after Pfizer drew praise from President Donald Trump for simply delaying planned price increases on 40 drugs...
Incyte/MSD's immunotherapy combo fails in Phase III pharmatimes
July 17, 2018
A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma.
Merck inks deal with China's Xian Janssen for type 2 diabetes drug biospectrumasia
July 16, 2018
China has more than 114 million people living with diabetes, the largest number of any country in the world

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page